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Antibody responses to two new 
Lactococcus lactis-produced recombinant 
Pfs48/45 and Pfs230 proteins increase with age 
in malaria patients living in the Central Region 
of Ghana
Festus K. Acquah1, Evans K. Obboh2, Kwame Asare3, Johnson N. Boampong3, Samuel Victor Nuvor4, 
Susheel K. Singh5,6, Michael Theisen5,6, Kim C. Williamson7,8 and Linda Eva Amoah1*
Abstract 
Background: Recent advances in malaria control efforts have led to an increased number of national malaria control 
programmes implementing pre-elimination measures and demonstrated the need to develop new tools to track and 
control malaria transmission. Key to understanding transmission is monitoring the prevalence and immune response 
against the sexual stages of the parasite, known as gametocytes, which are responsible for transmission. Sexual-stage 
specific antigens, Pfs230 and Pfs48/45, have been identified and shown to be targets for transmission blocking anti-
bodies, but they have been difficult to produce recombinantly in the absence of a fusion partner.
Methods: Regions of Pfs48/45 and Pfs230 known to contain transmission blocking epitopes, 6C and C0, respectively, 
were produced in a Lactococcus lactis expression system and used in enzyme linked immunosorbent assays to deter-
mine the seroreactivity of 95 malaria patients living in the Central Region of Ghana.
Results: Pfs48/45.6C and Pfs230.C0 were successfully produced in L. lactis in the absence of a fusion partner using a 
simplified purification scheme. Seroprevalence for L. lactis-produced Pfs48/45.6C and Pfs230.C0 in the study popula-
tion was 74.7 and 72.8%, respectively.
Conclusions: A significant age-dependent increase in antibody titers was observed, which suggests a vaccine tar-
geting these antigens could be boosted during a natural infection in the field.
Keywords: Malaria, Transmission-blocking, Pfs48/45, Pfs230, Lactococcus lactis, Seropositive
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Background
Malaria is still a disease of immense public health impor-
tance due to its prevalence and high rates of mortal-
ity in the tropics and developing countries, especially in 
children under five [1]. Global efforts to eliminate the 
disease have led to an increase in the search for trans-
mission reducing interventions that target the parasite 
stage required for transmission, called gametocytes, as 
well as the mosquito vectors. Currently, the main focus 
of elimination and pre-elimination control measures is 
to decrease the mosquito vector population as well as 
control parasitaemia by prompt treatment with effec-
tive anti-malarial. Unfortunately, most commonly used 
anti-malarials, including artemisinin-based combination 
therapy (ACT), do not effectively eliminate gametocytes 
and in endemic countries there are also many individuals 
with asymptomatic infections that never seek treatment 
and serve as an infectious reservoir. Control efforts would 
be greatly enhanced by the development of effective 
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vaccines, but to date these efforts have been complicated 
by antigenic diversity both within and between the dis-
tinct stages of the parasite that develop in the human 
host.
One current strategy is to develop a multi-component 
vaccine that targets antigens found at different parasite 
stages, including the stages required for transmission [1]. 
Pfs48/45 and Pfs230 are sexual stage antigens that are 
expressed on the surface of the intraerythrocytic, Plas-
modium falciparum gametocyte and become exposed 
on the surface of extracellular gametes in the mosquito 
midgut [2]. Within 10  min after a gametocyte-infected 
erythrocyte is taken up in a blood meal by a mosquito, the 
parasite emerges as an extracellular gamete. Emergence 
exposes surface-antigens, such as Pfs48/45 and Pfs230, 
to antibodies also present in the human blood meal. Both 
antigens elicit an immune response during a natural infec-
tion [3] and Pfs48/45 or Pfs230-specific antibodies have 
been shown to block transmission to mosquitoes in a 
standard membrane feeding assay (SMFA) [4–7]. How-
ever, despite their potentially important role in malaria 
transmission, these antigens have not been included in 
many field studies due the lack of properly-folded recom-
binant proteins. Therefore, relatively little is known about 
the epidemiology of the host response against these anti-
gens. Prior studies have used two-site or competition 
ELISAs to capture antigen from gametocyte extract using 
mAb then assaying for the ability of antibodies in human 
serum or plasma samples to bind or to compete with the 
binding of a second antibody, respectively [8–10]. These 
are elegant assays to test for antibody responses to defined 
epitopes, but require access to in vitro cultured parasites 
and monoclonal antibodies (mAb) making them difficult 
to include in most field studies. Additionally, the epitope 
recognized by the capture mAb is blocked and not acces-
sible to the test antibodies. An alternative is to generate 
properly folded recombinant protein and test directly for 
immunoreactivity; however Pfs48/45 and Pfs230 both 
contain multiple 6-cysteine (6-cys) domain motifs which 
complicates the expression of correctly-folded recom-
binant proteins in heterologous systems [11–13]. The 
inclusion of a fusion partner such as maltose binding 
protein (MBP) [14] or P. falciparum glutamate rich pro-
tein (GLURP.R0) [11, 15] facilitates folding and expres-
sion of the 6-cys component. However, both GLURP.
R0 and MBP are themselves immunogenic, requiring 
the antibody responses generated in an ELISA against 
the fusion partner to be subtracted from the overall 
response to the fusion protein [16]. Pfs230 has also been 
expressed using plant or cell-free wheat germ agglutinin 
expression systems, but both these methods require spe-
cialized techniques that are difficult to scale up [17, 18]. 
As an economical alternative to these methods, 
recom binant proteins that were specific for Pfs48/45 or 
Pfs230 were designed and produced using the Lactococcus 
lactis (L. lactis) expression system. This expression system 
has recently been used to produce properly folded chi-
meric GMZ2.48/45, which includes Pfs48/45 amino acid 
residues (aa 291–428), that induces transmission blocking 
antibodies in rats and is being developed as a vaccine can-
didate [11, 13]. A Tobacco Etch Virus (TEV) protease site 
was introduced between GMZ2 and Pfs48/45-6C compo-
nents of the chimeric GMZ2.48/45 to allow the efficient 
removal of the fusion partner. The L. lactis expression 
system was also used to produce the N-terminal region 
(amino acid residues 443–590) of the processed form of 
Pfs230 that is retained on the gamete surface after eryth-
rocyte emergence [17]. Previous work demonstrated that 
when this region of Pfs230, called C0, was produced in the 
wheat germ cell-free system the C0 recombinant protein 
induced antisera in mice that reduced the infectivity of P. 
falciparum to Anopheles stephensi mosquitoes in the pres-
ence of complement [17].
Both L. lactis-produced antigens were then used to 
determine immunoreactivity in 95 malaria patients in 
coastal Ghana. The results demonstrate that 74.7 and 
72.8% of the individuals were seropositive for Pfs48/45-
6C and Pfs230-C0LI, respectively, and there was a sig-
nificant age-dependent increase in titer. This work 
demonstrates the natural immunogenicity of these 
important transmission-blocking targets, which sug-
gests they could have the potential to boost a Pfs230 or 
Pfs48/45 vaccine response. The L. lactis antigens can 
also be used as tools for further analysis of the natural 
immune response against gametocytes.
Methods
Ethical statement
Archived sera used in this study were from a previ-
ous cross sectional study approved by the Institu-
tional Review Board of the University of Cape Coast 
(UCCIRB/28/09/3.1.1) in addition to the Ethical Review 
Board of the Ministry of Health, Ghana MOH (GHS-ERC 
17/01/12) and carried out in the Central Region of Ghana 
between 2011 and 2012. All participants and parents of 
minors were educated about the study and gave written 
consent prior to sample collection. All patient informa-
tion is treated as confidential.
Study site and sample acquisition
Samples for this study were collected from patients 
reporting to three district hospitals, one each in Abura 
Dunkwa, Twifo Praso and Assin Fosu, which are district 
capitals for the Abura-Asebu-Kwamankese, Twifo-Ati 
Morkwa and Assin North districts of the Central Region 
of Ghana (Fig. 1) from January to December 2012. These 
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districts have been shown to harbor parasites with vary-
ing drug resistance susceptibilities [19] and a parasite 
prevalence ranging from 11.4 to 15.4% [20].
This study utilized paired archived filter paper blood 
blots and serum samples from 95 volunteers who had 
been confirmed as P. falciparum positive at the three dis-
trict hospitals in a larger study conducted in 2012 and 
previously reported by Asare et al. [19].
Plasmid constructs and protein production
Pfs230‑C0Ll
The nucleotides encoding Pfs230-C0Ll (amino acid resi-
dues 443–590) were amplified from r230/MBP.C [21] 
using primers 230F443 and 230R590 (Additional file  1: 
Table S1) and Iproof™ High-Fidelity polymerase (Bio-
Rad Laboratory, USA). The PCR amplicon was double 
digested with BglII and BamHI and ligated into BglII-line-
arized pLEA2 plasmid, a L. lactis expression vector which 
has the P170 pH sensitive promoter, the SP310mut2 
secretion signal peptide [22] and also appends a C-ter-
minal hexa-histidine tag to the expressed protein (Fig. 2). 
The ligated product was cloned in E. coli (strain TOP10) 
and the inserts were verified by sequencing (Macro-
gen Company, Holland). pLEA2 plasmid containing the 
Pfs230-C0Ll coding sequence was transformed into L. 
lactis MG1363 strain by electroporation as previously 
Fig. 1 Map of the Central Region of Ghana showing the study districts
a
b
Fig. 2 Schematic diagram of Lactococcus lactis based plasmids for 
expression of GMZ2.tev.6C (a) and Pfs230-C0LI (b) proteins. Both plas-
mids contain the pH inducible P170 promoter and DNA sequences 
that attaches a hexahistidine tag to the C-terminus of the expressed 
proteins. The coding region for the TEV protease recognition 
sequence used was ENLYFQG
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described [23]. After overnight growth in a bio fermenter 
[11, 15], the Pfs230-C0LI containing media was harvested 
by centrifugation at 9000×g for 15 min. The supernatant 
was filtered and diluted tenfold with equilibration buffer 
(50 mM Tris HCl, 200 mM NaCl, 25 mM imidazole, pH 
8.0) and the Pfs230-C0Ll protein was affinity-purified on 
a 5  ml HisTrap Crude FF column on the  AKTAXPRESS 
FPLC system. The column was washed with equilibration 
buffer to remove unbound proteins and then bound pro-
teins were eluted with a 0–400 mM imidazole gradient in 
elution buffer (50 mM Tris HCl, 200 mM NaCl, 400 mM 
imidazole, pH 8.0) at a flow rate of 0.8 ml/min.
Lactococcus lactis expression plasmid, pGMZ2.tev.6C 
(Fig.  2), containing DNA encoding the Glutamine Rich 
Protein (GLURP.R0, nt 79–1500) and the Merozoite Sur-
face Protein 3 (MSP3, nt 462–747) domain cassette and 
the C terminal region of Pfs48/45 (6C, nt 871–1284), 
with a TEV protease recognition site (ENLYFQG) at the 
MSP3 and 6C junction was constructed analogous to 
pGMZ2.6C [13]. However, the synthetic 285  bp MSP3 
fragment was amplified with the TevF1 and TevR1 prim-
ers (Additional file 1: Table S1) using HotStar HiFidelity 
polymerase (Qiagen), to incorporate ENLYFQG at the 3′ 
end of the fragment prior to insertion into pSS2. The final 
plasmid, pGMZ2.tev.6C, containing the TEV protease 
site was transformed into L. lactis MG1363 [23] and fer-
mented as previously described [15]. Culture medium 
containing secreted GMZ2.tev.6C protein was har-
vested, then concentrated tenfold and buffer exchanged 
into phosphate-buffered saline, pH 7.2 (PBS) contain-
ing 10  mM imidazole, using the QuixStand system (GE 
Healthcare, Sweden) followed by affinity purification 
using an HisTrap HP column (GE Healthcare) as previ-
ously described [11]. Recombinant TEV protease was 
produced and purified from expression vector, pRK793 
as detailed by the manufacturer [24]. The purified GMZ2.
tev.6C protein was digested overnight at 4 °C with a 1:10 
concentration of TEV protease. The TEV-digested pro-
tein was diluted tenfold with 50 mM Tris, pH 8.0 and ion 
exchange chromatography on a 5 ml HiTrap Capto Q col-
umn (GE Healthcare) was performed for the separation 
of GMZ2, 6C and the TEV protease.
Protein characterization
Crude or purified protein fractions were subjected to 
SDS-PAGE on 4–12% BisTris gel at 150  V for 1  h and 
stained with Coomassie blue or transferred to a hybond-
ECL nitrocellulose membrane at 35 V for 1 h for subse-
quent immunoblotting. After transfer, the membrane was 
blocked with 5% skimmed milk in 1× PBS with 0.0 5% 
Tween 20 for 2  h before adding the indicated antibody. 
Horseradish peroxidase (HRP)-conjugated anti-His(C-
term) antibodies (Thermo Scientific) were used to detect 
the presence of purified GMZ2.tev.6C and its digested 
products. The absence of any GLURP.R0 contaminant 
in the final purified cleaved 6C protein was determined 
by probing the immunoblot with polyclonal rabbit anti-
GLURP.R0 antibodies and HRP conjugated anti-His(C-
term) antibodies (Thermo Scientific). Polyclonal 
antibodies against Escherichia coli expressed Pfs230C 
followed with HRP-conjugated anti-mouse IgG were 
used to detect Pfs230-C0Ll. Pierce ECL Western Blotting 
Substrate (Thermo Scientific) or 3,3′-diaminobenzidine 
tetrahydrochloride (D5905, Sigma Life Sciences) used as 
a substrate for visualization. Folding of Pfs48/45-6C anti-
gen was determined as previously described [11].
Pfs48/45‑6C and Pfs230‑C0Ll ELISA
NUNC Maxisorp 96-well ELISA plates were coated 
with 100  µl of 1  µg/ml of affinity purified Pfs230-C0Ll 
or Pfs48/45-6C in carbonate buffer (0.05  M carbon-
ate/bicarbonate buffer, pH 9.2) overnight at 4  °C. 
Plates were blocked with 150 µl of blocking buffer (3% 
skimmed milk in 1× PBS supplemented with 0.0 5% 
Tween 20 (PBST)) for 2  h. Following this, plates were 
washed three times with PBST and then incubated for 
2 h at room temperature with 100 µl of test serum from 
malaria infected individuals (1/200 dilution in PBST) 
or a pool of negative control serum from donors liv-
ing in non-endemic countries. The wells were then 
washed three times and 100 µl of polyclonal rabbit anti-
human IgG-HRP (1/3000 dilution in 1× PBS with 0.0 
5% Tween 20) was added to each well and incubated for 
2  h. Plates were washed four times and then 100  µl of 
tetramethylbenzidine substrate solution was added per 
well and incubated for 20 min. Reactions were stopped 
using 100 µl per well of 0.2 M sulphuric acid and opti-
cal densities were measured at 450 nm using the ELx808 
Absorbance Reader (BioTek). Optical densities (OD) 
of the serum samples obtained from each ELISA plate 
were transformed into IgG concentrations (ng/μl) based 
on the regression curve obtained from titrating purified 
human polyclonal IgG (PB055, The Binding Site) on the 
corresponding plate.
Genomic DNA extraction, PCR and sequencing
Chelex in PBS was used to extract DNA from dried fil-
ter paper blood blots from 95 donors whose sera were 
used for ELISA [25]. Briefly, two 3 mm circles were cut 
from each blood blot using a 3 mm2 punches and placed 
in a 1.5 ml microcentrifuge tube. 1 ml of 0.02% saponin 
was added to each tube and agitated overnight (~17 h) at 
room temperature. The saponin solution was decanted 
and the blots washed with 1× PBS solution. 150 µl of a 
6% Chelex/PBS solution was added to the washed blots, 
which were then incubated at 95 °C for 10 min in a water 
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bathe. The extracted DNA served as a template for PCR 
amplification of fragments of both the Pfs48/45 and the 
Pfs230 genes, that encompass the regions of the genes 
used to produce the antigens used in this study. PCR 
amplicons were purified using the DNA clean and con-
centrator kits (Zymo) and subsequently sent together 
with the forward and reverse primers to MWGBiotech 
for bidirectional sequencing.
Data analysis
Data was analysed using Microsoft Excel 2013 and 
GraphPad Prism v7 (GraphPad Software Inc.). Kruskal–
Wallis test of variance and Duns test were used to deter-
mine significant difference among the mean values of 
Pfs48/45, Pfs230 antibodies and parasite density within 
the stratified study population. Shapiro–Wilk normality 
test was also used to test for normality in the distribution 
of log transformed antibody concentrations. ADAMSEL 
(Ed Remarque, BPRC) was used to analyze the ELISA 
data and convert the optical densities (OD) into concen-
tration. BioEdit v7.2.6 (Tom Hall) and MAFFT online 
sequence alignment (Kazutaka Katoh) programs were 
used to assess the polymorphisms in the genes. Effects of 
mutations on protein sequence were also determined by 
EXPASY online translate tool [26].
Results
Recombinant Pfs48/45‑6C and Pfs230‑C0Ll expression
The nucleotides encoding the C terminal fragment of 
Pfs48/45 (bp 871–1284) containing epitope I, Pfs48/45-
6C, and Pfs230 region C0 (bp 1329–1770), Pfs230-C0Ll, 
were successfully cloned using primers listed in Addi-
tional file  1: Table S1 into L. lactis expression plas-
mids pSS2 and pLEA2 to form the pGMZ2.tev.6C and 
pPfs230-C0Ll constructs, respectively (Fig.  2). Both 
recombinant proteins were successfully expressed by 
L. lactis (Figs.  3, 4) and purified using nickel-nitrilotri-
acetic acid (NTA) column. As expected the chimeric 
GMZ2/Pfs48/45-6C recombinant protein (GMZ2.tev.6C, 
yield 25  mg/l from overnight fermentation) strongly 
reacted with anti-GLURP.R0 (Fig. 3b, lanes 2 and 3) and 
HRP-conjugated anti-His(C-term) antibodies (Thermo 
Scientific) (Fig. 3c, lanes 2 and 3) prior to TEV protease 
treatment. TEV digestion generated two fragments of the 
expected sizes as well as a small amount of residual undi-
gested full-length protein (Fig. 3a, b, lane 4). This residual 
undigested full-length protein still retains the C-terminal 
Histidine (His) tag and is detected with anti-His(C-term) 
antibodies (Fig.  3c, lane 4). The released Pfs48/45.6C 
fragment was subsequently purified over the CaptoQ col-
umn (GE Healthcare Life Sciences) (Fig. 3, lane 5) with a 
a b c
Fig. 3 Expression and purification of Pfs48/45-6C by L. lactis. Culture supernatant (lane 2), Ni–NTA purified GMZ2.tev.6C protein (lane 3), TEV 
digested GMZ2.tev.6C (lane 4) and purified Pfs48/45.6C (lane 5) were subjected to SDS-PAGE and subsequently to Coomassie blue staining (a) or 
Western blotting using anti-GLURP.R0 (b) or anti-His(C-term) (c)
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yield of 5 mg/l. The purified Pfs48/45.6C antigen did not 
react with polyclonal GLURP.R0 antibodies (Fig. 3b, lane 
5) but reacted with anti-His(C-term) antibodies (Fig. 3c, 
lane 5), suggesting that there was no GLURP.R0 contami-
nation in the final product.
Lactococcus lactis expressed Pfs230-C0Ll was success-
fully purified in a single step using a HisTrap Crude FF 
column (Fig.  4) yielding 15.4  mg/l of pure protein from 
culture medium harvested after overnight growth with-
out fermentation. Affinity purified Pfs230-C0LI was rec-
ognized by antibodies against a C-terminal polyhistidine 
tag (Fig.  4b, lane 2) and mouse polyclonal antibodies 
generated against E. coli expressed Pfs230C recombinant 
protein (Fig. 4c, lane 2) [7].
Both recombinant proteins were used to evaluate 
the immune response against these sexual stage anti-
gens. The study population included 95 symptomatic 
malaria patients, 20 (21.1%) of the samples were from 
volunteers resident in Abura Dunkwa, 44 (46.3%) were 
from Assin Fosu and 31 (32.6%) from Twifo Praso. The 
geometric mean age of the study population was 7.045 
(CI 5.56–8.92) years and geometric mean P. falciparum 
parasite density of 7464 (CI 5227–10,659) parasites/μl. 
As is typical in many field studies, where the main inter-
est is asexual parasite density, gametocyte data was not 
recorded in any of the thick smears prepared from the 
study participants. 65% of the volunteers were female 
(Table  1). Although there was no significant difference 
between parasite densities across the study population, 
there was a general trend of decreased parasite load in 
the older population compared to children 5  years and 
below (P  =  0.107) (Table  1). A similar trend was seen 
with haemoglobin concentrations as might be expected 
since PD can influence HB. The geometric mean of the 
hemoglobin concentrations within the entire study pop-
ulation was 9.54 (CI 9.16–9.93) g/dl (Table 1), while the 
geometric mean level in children 5 years and below was 
lower at 8.93 (CI 8.27–9.65) g/dl but not significantly dif-
ferent (P = 0.072) from the older children or the adults 
(Table 1).
Seroprevalence of antibodies against recombinant Pfs230 
and Pfs48/45 antigens
This study set out to utilize newly produced sexual stage 
antigens to determine whether the immune response in 
malaria patients in the Central Region of Ghana varied 
with age, PD or HB levels, which have been associated 
with increased gametocyte carriage [27, 28]. The percent-
ages of malaria-infected individuals who had antibody 
responses against Pfs230-C0Ll or Pfs48/45-6C that were 
(two standard deviations) higher than those observed 
for the pooled negative control serum (159 ±  55.4 and 
312  ±  46.6  ng/ml), respectively, were determined in 
an indirect ELISA. It was observed that 72.8% of the 
malaria-infected study population was seropositive for 
a b c
Fig. 4 Expression of hexahistidine tagged Pfs230-C0Ll by L. lactis. 
Culture supernatant (Gel A, lane 2), and purified antigens (lane 3 of 
gel A and lane 2 of gel B and C) were subjected to SDS-PAGE and sub-
sequently stained with Coomassie blue (a) or western blotting with 
anti-His(C-term) (b) or anti-Pfs230C antibodies (c) as probe.  Novex® 
Sharp Prestained Protein Standard was used in lane 1 of gel A, B and C
Table 1 Clinical features of participants at presentation
HB (g/dl) Age (years) PD (/µl)
Total 0–5 6–17 ≥18 Total 0–5 6–17 ≥18 Total 0–5 6–17 ≥18
Count 90 37 23 30 95 39 23 33 90 36 23 31
Minimum 4.4 4.4 7 7.3 0.33 0.33 6 18 40 40 680 240
Maximum 13.6 12 13.6 11.6 35 5 17 35 184,600 184,600 109,080 84,000
Geometric mean (GM) 9.54 8.93 10.04 9.95 7.045 2.162 9.59 22.94 7464 9313 10,271 4555
Lower 95% CI of GM 9.16 8.27 9.28 9.54 5.56 1.71 8.10 21.5 5227 4957 5478 2530
Upper 95% CI of GM 9.93 9.65 10.86 10.37 8.92 2.72 11.35 24.49 10,659 17,498 19,259 8202
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Pfs230-C0Ll while 74.7% were seropositive for Pfs48/45-
6C antigen. The seroprevalence was similar in different 
age groups (P  =  0.10) (Fig.  5a), however adults (above 
17  years) had significantly higher antibody [29] levels 
against both Pfs48/45-6C and Pfs230-C0Ll than the young 
children (0–5 years) with P values of 0.0037 and less than 
0.0001, respectively (Fig. 6a; Additional file 2: Table S2). 
Consistent with an age dependent response, only indi-
viduals older than 5  years of age had anti-Pfs48/45-6C 
titers that were fourfold or more above the pooled nega-
tive serum (high responders) (Fig.  5c). A broader range 
of titers was obtained against Pfs230-C0Ll, with all ages 
represented in the high responder category (Fig.  5b). 
Older children and adults were still the majority of the 
high Pfs230-C0Ll responders, while younger children 
were more likely to be low or medium responders and 
older children were equally distributed between all three 
categories. 
Gene polymorphisms
To evaluate whether antigen polymorphisms in the local 
parasite populations could affect immunoreactivity 
against the recombinant proteins that corresponded to 
lab strain 3D7 parasites, the corresponding genes were 
amplified from DNA obtained from subject blood sam-
ples. Polymorphisms in the gene fragments encoding 
Pfs230-C0Ll and Pfs48/45-6C were assessed using prim-
ers listed in Additional file  1: Table S1. Polymorphisms 
observed are summarized in Table 2. The main polymor-
phism identified in the Pfs230-C0 region was a deletion 
of nucleotides 1559–1567 which occurred in 4 out of the 
13 successfully sequenced samples (Table  2; Additional 
file 4: Figure S1). This polymorphism deletes one of the 
two tandem ‘YGE’ sequences, but does not change the 
reading frame. In Pfs48/45, the mutation identified was 
a T940A, which has the downstream effect of changing 
leucine to isoleucine in the protein and occurred in 12 
Fig. 5 Seroprevalence of anti-Pfs48/45.6C and Pfs230-C0Ll antibodies. a The proportion of young children (0–5 years), older children (6–17 years) 
and adults (above 17 years) who were seropositive for Pfs48/45 and Pfs230 using L. lactis expressed Pfs48/45-6C and Pfs230-C0Ll antigens. Antibody 
responses to Pfs48/45-6C (b) and Pfs230-C0LI (c) were categorized as low (≤twofold higher than the negative control cutoff, medium (between 
two and fourfold higher than the negative control cutoff ) or high (≥fourfold higher than the negative control cutoff ). The percentage of young 
children, older children and adults that were seropositive with low, medium and high antibody levels against Pfs48/45-6C (b) or Pfs230-C0Ll (c) were 
plotted. The exact number of patients sampled in each age group is listed in Additional file 2: Table S2
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out of 19 sequenced DNA samples (Table  2; Additional 
file  4: Figure S1). The antibodies from subjects infected 
with parasites with these mutations still recognized 
Pfs48/45-6C and Pfs230-C0Ll (Additional file 3: Table S3), 
suggesting the changes did not have a major impact on 
the immune response of these subjects or that the anti-
bodies were elicited by a previous infection.
Discussion
This study demonstrates the successful expression of 
Pfs230- and Pfs48/45-specific antigens, Pfs230-C0Ll 
and Pfs48/45-6C, respectively. The parental chimeric 
Pfs48/45-6C has been shown to induce antibodies that 
inhibit malaria transmission in a SMFA [11] and TEV 
cleavage was not found to alter that structure, while 
Pfs230-C0Ll reacts with antibodies produced against 
recombinant Pfs230 region C, which have transmission-
blocking activity [30]. Together the two antigens provide 
new, economical tools to monitor immunoreactivity in 
human blood samples. L. lactis is a current good manu-
facturing practice (cGMP), scalable expression system 
that allowed the purification of Pfs230-C0Ll antigen from 
culture media in one step to yield 1.54 mg of pure protein 
from a 100  ml of an overnight benchtop culture. It is 
likely that much higher yields could be obtained if the 
construct is fermented in a 1l biofermentor. Secretion of 
the recombinant protein into the culture media simplifies 
purification by bypassing the need to lyse the bacteria, 
making the process more consistent as well as less labori-
ous. The Pfs48/45-6C domain was produced as a fusion 
with GLURP.R0/MSP3, purified from the culture media 
using Nickel-resin at 25 mg/l and then efficiently released 
from GLURP.R0/MSP3 using TEV protease and repuri-
fied by ion exchange. Initially a mAb affinity purification 
step was included after the ion exchange chromatogra-
phy, but our desire to produce a scalable antigen and our 
experience from the purification of GLURP.R0.6C [11] 
lead us to do away with the unscaleable mAb purification 
step, which did not significantly enhance the purity.
A recent study conducted in the Central Region of 
Ghana identified a high proportion of children who 
harbored submicroscopic gametocytes [31], but did 
not investigate how gametocyte carriage influences the 
acquisition of antibodies against these life stages of the 
parasite. This study thus set out to utilize newly produced 
sexual stage antigens to determine the baseline responses 
individuals in the Central Region of Ghana generate 
against the selected gametocyte antigens.
Using both purified antigens to evaluate natural anti-
body responses in malaria patients from the Central 
Region of Ghana, the seroprevalence of antibodies 
against Pfs230-C0Ll and Pfs48/45-6C was 72.8 and 74.7% 
respectively. The similar seroprevalence rates against 
these two sexual stage antigens is consistent with the 
similar gametocyte-specific expression patterns of Pfs230 
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Fig. 6 Antibodies titers against L. lactis expressed Pfs48/45-6C (a) and Pfs230C0Ll (b) antigens, respectively in the total study population. An ELISA 
was used to test recombinant antigens for reactivity with serum from malaria infected children and adults living in the Central Region of Ghana. All 
serum samples (1:200 dilution) were tested in duplicate and repeated at least twice. Optical densities (OD) for the serum samples were obtained 
from each ELISA plate and transformed into IgG concentrations (ng/μl) based on the regression curve obtained from titrating purified human 
polyclonal IgG (PB055, The Binding Site) on the corresponding plate. The graph shows the geometric mean of the antibody concentrations plus or 
minus the 95% confidence interval. The exact number of patients sampled in each age group is listed in Additional file 2: Table S2
Table 2 Mutations in  genes encoding Pfs230-C0Ll and   
Pfs48/45-6C
Frequency is defined as the number of samples with mutation/total successfully 
sequenced samples
Antigen Mutation Translation Frequency
Pfs48/45-6C T940A L → I 12/19
Pfs230-C0Ll 1559–1567 ‘YGE’ deletion 4/13
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and Pfs48/45 and suggests that the immune response 
may be associated with gametocyte exposure, as was 
previously reported in a longitudinal study in Tanzania 
using a two-site ELISA with purified gametocyte extract 
as antigen [10]. A significant positive association between 
the concentrations of antibodies recognizing Pfs230-C0Ll 
and Pfs48/45-6C in individuals (r =  0.378, P =  0.0002) 
is further support for a coordinated immune response 
against the two antigens, which would be expected if 
gametocyte exposure stimulated immunoreactivity. For 
both antigens, antibody titers increased significantly with 
age, which is suggestive of the development of immuno-
logical memory that could be boosted by exposure to a 
vaccine containing similar regions of Pfs230 or Pfs48/45 
or natural exposure to the sexual stages of the malaria 
parasite. Age-dependence of Pfs230-C0Ll and Pfs48/45-
6C antibody responses was also reported in the longi-
tudinal study in Tanzania mentioned above and in Irian 
Jayian transmigrants [32], but has not been observed in a 
number of other studies evaluating Pfs230 and Pfs48/45 
using a two site ELISA [8, 9]. A recent cross-sectional 
study of healthy school children in the Eastern region 
of Ghana, reported low Pfs230 and Pfs48/45 antibody 
seroprevalence, 20.7 and 15.2%, respectively and no age 
dependence using recombinant Pfs48/45 region 10C (aa 
172–428) and Pfs230 region CMB (aa 444–730) [33]. The 
difference between this cross sectional study and our 
evaluation of malaria patients, could be due in part to a 
relatively short-lived antibody responses to Pfs230 and 
Pfs48/45, which have been reported previously [8, 34]. 
The evaluation of malaria patients that are likely to have a 
high prevalence of submicroscopic levels of gametocytes 
could contribute to the high seroprevalence observed. 
To address this directly, longitudinal studies are needed 
that monitor gametocyte exposure and the responses of 
the same children before and after an infection. Under-
standing the persistence of antibody responses in the 
presence and absence of parasite exposure is critical to 
vaccine design and administration. In the future it will 
also be important to directly determine whether the spe-
cific human antibodies that recognize these antigens have 
transmission-blocking activity.
Antigenic polymorphisms are also an important con-
sideration when evaluating field samples. Although, more 
limited than some asexual stage surface antigens, sexual 
stage antigens have been found to be polymorphic [35]. 
Genomic DNA sequence from parasites isolated from the 
blood of 19 subjects revealed a T940A mutation in the 
6C region (bp 859–1284) of Pfs48/45 (Table 2; Additional 
file 4: Figure S1) in 12 individuals. This mutation changes 
leucine (aa 314) to isoleucine, another hydrophobic 
amino acid and is also a predominant mutation in other 
field samples [36]. No other Pfs48/45 mutation was found 
in the region of the isolates that were sequenced in this 
study. The mutation identified in the C0 region (bp 1329–
1764) of Pfs230 was a deletion of 9 nucleotides 1559–
1567 in four samples (Table  2; Additional file  4: Figure 
S1). This mutation deletes one of the duplicated YGEs 
(aa 521–526) in the 3D7 reference parasite sequence. 
Deletions or additions in regions of tandem amino acid 
repeats are not uncommon in the Pfs230 gene sequence 
[17]. These small changes were not found to have a major 
impact on the immune response observed in this study 
against Pfs230-C0Ll and Pfs48/45-6C (Additional file  3: 
Table S3).
Conclusion
Plasmodium falciparum sexual stage antigens, Pfs230-
C0Ll and Pfs48/45-6C have been produced using in a scal-
able, L. lactis expression system that can be used as tools 
for monitoring natural immune responses. In addition 
to high antibody prevalence in malaria patients in the 
Central region of Ghana, antibody titers increased sig-
nificantly with age, which is consistent with the develop-
ment of immunological memory against these important 
transmission-blocking candidates.
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